We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Breakthrough Endoscopic Biopsy Device Enables Definitive Diagnosis of GI Cancers

By HospiMedica International staff writers
Posted on 13 Sep 2023
Print article
Image: The Precision GI endoscopic ultrasound biopsy device has received US FDA 510(k) clearance (Photo courtesy of Limaca Medical)
Image: The Precision GI endoscopic ultrasound biopsy device has received US FDA 510(k) clearance (Photo courtesy of Limaca Medical)

Endoscopic biopsies serve a crucial role in the precise and timely treatment of cancer by allowing for histologic and genetic testing of tissues. The traditional tools used for these procedures are manual Endoscopic Ultrasound (EUS) needles, which come with several drawbacks. They often throw up several challenges like inconsistent biopsy results, dependency on high-level skills, low standardization, multiple needle passes, suboptimal tissue samples for analysis, and higher rates of insufficient tissue during molecular testing. Now, an automated, motorized endoscopic biopsy device has the potential to improve biopsy results for the evaluation of gastrointestinal (GI) malignancies.

Limaca Medical (Yokneam, Israel) has developed the Precision GI EUS biopsy device, marking a major leap forward in obtaining biopsies for a confirmed diagnosis of pancreatic and other severe GI cancers. Unlike existing tools, this automated device is engineered to more efficiently and effectively diagnose GI cancers by securing substantially better quality and greater amounts of biopsy tissue that is crucial for diagnosis. Traditional endoscopic biopsy devices often fall short in consistently collecting quality and adequate tissue samples, leading to issues like fragmented tissue, insufficient volume, and blood contamination.

Physicians are increasingly favoring the Precision GI EUS biopsy device over older endoscopic biopsy tools because of its capability to obtain higher quality and larger tissue samples necessary for in-depth histological and molecular examinations. Furthermore, the device standardizes outcomes, making it effective across a wide range of physician skill sets. The U.S. Food and Drug Administration (FDA) has given 510(k) clearance to Limaca's Precision GI EUS biopsy device, following the company's earlier FDA Breakthrough Device Designation for the same product.

"Our first series of patients have demonstrated that Precision GI enables obtaining contiguous intact core tissue samples adequate for definitive diagnoses of pancreatic lesions,” said Assaf Klein, Limaca CEO. “The clean, non-contaminated tissue samples provide a high percentage of tumor content, with less blood and extraneous fluids. FDA clearance allows us to bring Precision GI to market to fulfill our mission to always achieve precise, efficient, and definitive biopsy samples."

"We are pleased with FDA's clearance of Precision GI, following our FDA Breakthrough Device Designation,” added Carl Rickenbaugh, Limaca Vice Chair. “We are dedicated to our mission to provide a far better endoscopic biopsy experience for the endoscopist and patient, with the goal of achieving faster, more efficient biopsy yield with highly consistent results. We look forward to soon bringing Precision GI to patients in the US."

Related Links:
Limaca Medical

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Flocked Fiber Swabs
Puritan® patented HydraFlock®
New
Ultra-Flat DR Detector
meX+1717SCC
New
Tabletop Steam Autoclave
T24

Print article
Radcal

Channels

Critical Care

view channel
Image: The Biointegrated Implantable Systems for Cell-based Sensing and Therapy technology can be used to treat various diseases (Photo courtesy of 123RF)

Implantable Cell-Based Bioelectronic Devices to Enable Patient-Specific Treatment and Disease Monitoring

Researchers are advancing the development of implantable, cell-based bioelectronic devices designed to provide personalized therapy and monitor disease conditions such as hypo- and hyperthyroidism in real-time.... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
The Atellica VTLi Patient-side Immunoassay Analyzer, a high-sensitivity troponin I test at the bedside, delivers accurate results in just 8 minutes (Photo courtesy of Siemens Healthineers)

New 8-Minute Blood Test to Diagnose or Rule Out Heart Attack Shortens ED Stay

Emergency department overcrowding is a significant global issue that leads to increased mortality and morbidity, with chest pain being one of the most common reasons for hospital admissions.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.